LIVE ATTENUATED VACCINES FOR PANDEMIC PREPAREDNESS

用于预防流行病的减毒活疫苗

• 批准号: 6286118
• 负责人: SHENGQIANG LI
• 金额: $ 2.6万
• 依托单位: MEDIMMUNE VACCINES, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-05-03 至 2000-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6286118
• 关键词: attenuated microorganism; communicable disease control; influenza; influenza vaccines; influenzavirus A; vaccine development

Most influenza experts agree that we are "due" for an influenza pandemic. One potential method of protecting public health in the threat of a pandemic would be mass immunization. The research program being proposed will evaluate the feasibility of developing, manufacturing, and distributing a live attenuated vaccine which could ultimately be tested in humans for potential use during an influenza pandemic. The objective will be to test the hypothesis that vaccination with a live attenuated vaccine based on a pandemic virus strain is a feasible and practical way of controlling the spread of influenza during a threat of a pandemic. Aviron is developing a live attenuated vaccine for general use in the prevention of influenza, and is interested in applying this technology to pandemic preparedness efforts in developing a vaccine candidate, as well as building related competencies to ensure widespread vaccination is feasible. Specifically, this research program will determine: the feasibility of generating reassortants containing HA and NA genes derived from avian influenza virus and remaining genes from the cold-adapted A/Ann Arbor/6/60 virus using classic reassortment technique; the characterization and safety evaluation of the reassortants in vitro and in animal models; manufacturing such a vaccine including the release protocols to ensure appropriateness for human testing; the potential for usefulness (in providing safety and efficacy) of the vaccine candidate in providing protection in humans; and the methods required for rapid, efficient distribution and administration of the vaccine to large numbers of people.

大多数流感专家都认为，我们“应该”面对一场流感大流行。 大规模免疫是在大流行威胁下保护公众健康的一种潜在方法。 拟议中的研究计划将评估开发、制造和分发减毒活疫苗的可行性，这种疫苗最终可能在人类身上进行测试，以便在流感大流行期间使用。 目的是检验以下假设：在大流行威胁期间，接种基于大流行病毒株的减毒活疫苗是控制流感传播的可行和实用方法。 阿维龙正在开发一种减毒活疫苗，用于预防流感，并有意将这一技术应用于大流行病防备工作，以开发候选疫苗，并建立相关能力，确保广泛接种疫苗是可行的。具体而言，该研究计划将确定：使用经典重配技术制备含有来自禽流感病毒的HA和NA基因以及来自冷适应A/安阿伯/6/60病毒的剩余基因的免疫剂的可行性;体外和动物模型中免疫剂的表征和安全性评价;制造这样的疫苗，包括释放方案，以确保适合人体试验;候选疫苗在提供人类保护方面的有用性（在提供安全性和有效性方面）的潜力;以及向大量人群快速、有效地分发和接种疫苗所需的方法。